Launch of the Phase III Clinical Trial for KRP-116D
First written in FY2017. 3 of 7 entries say "Advanced", first in FY2020-Q1. Latest entry: FY2022-Q2.
No other company in this theme has enough history to compare yet.
- FY2022-Q2Cited as achievedAnnual report
「Jimso Intravesical Solution 50%, an interstitial cystitis treatment that received marketing approval in January 2021, was launched in April of the same year.」
For KRP-116D, the April 2021 launch following marketing approval is reiterated as an achievement after completion of development. - FY2022-Q1AdvancedAnnual report
「Jimso Intravesical Solution 50%, an interstitial cystitis treatment that received marketing approval in January 2021, was launched in April of the same year.」
KRP-116D progressed from obtaining marketing approval in January 2021 to its launch in April of the same year. - FY2021-Q3AchievedAnnual report
「The company obtained marketing approval in January 2021 for the interstitial cystitis treatment Jimso Intravesical Solution 50% (development code: KRP-116D).」
KRP-116D completed the process through obtaining marketing approval. - FY2020AdvancedAnnual report
「In March 2020, the company submitted an application to the Ministry of Health, Labour and Welfare for marketing approval of the interstitial cystitis treatment KRP-116D.」
KRP-116D progressed from the application-preparation stage to the submission of its marketing approval application in March 2020. - FY2020-Q3RestatedAnnual report
「The development pipeline products in the application-preparation stage also included the quinolone injectable antibacterial agent KRP-AM1977Y and the interstitial cystitis treatment KRP-116D.」
KRP-116D continues to be listed as a development pipeline product in the application-preparation stage. - FY2020-Q1AdvancedAnnual report
「The company devoted maximum effort to preparing for regulatory applications for 3 development pipeline products that had moved into the application-preparation stage in the previous fiscal year: the combination asthma treatment KRP-108P, the quinolone synthetic antibacterial agent KRP-AM1977Y, and the interstitial cystitis treatment KRP-116D.」
KRP-116D was described as having moved into the application-preparation stage after the start of its Phase III trial. In this filing, the development code remains KRP-116D. - FY2017First statedAnnual report
「We began a Phase III clinical trial in March 2017 for KRP-116D, a treatment for interstitial cystitis, whose generic name is dimethyl sulfoxide.」
A Phase III clinical trial for KRP-116D began in March 2017.